| Título: | Antiphospholipid Antibodies in Neoplastic Patients |
| Autores: |
Mortazavizadeh, MR Sadeghmanesh, R |
| Fecha: | 2012-04-16 |
| Publicador: | Shahid Beheshti University of Medical Sciences |
| Fuente: |
Ver documento |
| Tipo: |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| Tema: | No aplica |
| Descripción: | AbstractBackground: Anti-phospholipid syndrome (APS) is an autoimmune systemic disease characterized by the persistent presence of anti-phospholipid antibodies (APA) and the occurrence of thrombotic events. Nowadays, the association between specific antibodies for anionic phospholipids with thrombotic events and other main clinical manifestations is well-recognized as "antiphospholipid syndrome". The present study was done to evaluate the frequency of antiphospholipid antibodies in neoplastic patients.Material and methods: One hundred and eighty patients were included in this cross sectional study. Their suspected neoplasm disorders were confirmed by pathology or flowcytometry. History taking and clinical examination were done for patients to detect all symptomatic clinical thrombotic events. Antiphospholipid antibodies were tested for all patients.Results: The study was concluded with 156 study samples. Thirty three patients (21.2%) had antiphospholipid antibodies. There was no significant difference on antiphospholipid antibodies frequency between two genders. APA frequency showed no significant difference between solid or non-solid tumors. The rate of thrombosis was significantly higher in neoplastic patients with antiphospholipid antibodies.Conclusion: Frequency of antiphospholipid antibodies was significantly higher in neoplastic patients. Antiphospholipid antibodies were one of the multifactorial accelerating factors for thrombotic events in neoplastic patients.Keywords: antiphospholipid antibody; thrombotic events; neoplastic patient References1. Raschi E, Testoni C, Borghi MO, Fineschi S, Meroni PL. Endothelium activation in the anti-phospholipid syndrome. Biomed Pharmacother. 2003 Sep;57(7):282-6.2. Vermylen J, Van Geet C, Arnout J. Antibody-mediated thrombosis: relation to the antiphospholipid syndrome. Lupus. 1998;7 Suppl 2:S63-6.3. Roubey RA. Update on antiphospholipid antibodies. Curr Opin Rheumatol. 2000 Sep;12(5):374-8.4. Ishikura K, Wada H, Kamikura Y, Hattori K, Fukuzawa T, Yamada N, et al. High prevalence of anti-prothrombin antibody in patients with deep vein thrombosis. Am J Hematol. 2004 Aug;76(4):338-42.5. Pierangeli SS, Harris EN. Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. Lupus. 2003;12(7):539-45.6. Miesbach W. Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment. Semin Thromb Hemost. 2008 Apr;34(3):282-5.7. Timuragaoglu A, Duman A, Ongut G, Saka O, Karadogan I. The significance of autoantibodies in non-Hodgkin's lymphoma. Leuk Lymphoma. 2000 Dec;40(1-2):119-22.8. Stasi R, Stipa E, Masi M, Oliva F, Sciarra A, Perrotti A, et al. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma. Thromb Haemost. 1993 Oct 18;70(4):568-72.9. Lossos IS, Bogomolski-Yahalom V, Matzner Y. Anticardiolipin antibodies in acute myeloid leukemia: prevalence and clinical significance. Am J Hematol. 1998 Feb;57(2):139-43.10. Malnick SD, Geltner D, Sthoeger Z. Anticardiolipin antibody associated with renal carcinoma. J Rheumatol. 1995 Oct;22(10):2007-8.11. Yoon KH, Wong A, Shakespeare T, Sivalingam P. High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus. 2003;12(2):112-6.12. Ozguroglu M, Arun B, Erzin Y, Demir G, Demirelli F, Mandel NM, et al. Serum cardiolipin antibodies in cancer patients with thromboembolic events. Clin Appl Thromb Hemost. 1999 Jul;5(3):181-4.13. Sack GH, Jr., Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 1977 Jan;56(1):1-37.14. Aderka D, Brown A, Zelikovski A, Pinkhas J. Ideopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer. 1986;57:1846_9.15. Lieberman JS, Borrero J, Urdaneta E, Wright IS. Thrombophlebitis and cancer. JAMA. 1961 Aug 26;177:542-5.16. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998 Apr 23;338(17):1169-73.17. Goldberg R, Seneff M, Gore J, Anderson F, Greene H, Wheeler H, et al. Occult malignant neoplasm in patient with deep venous thrombosis. Arch Intern Med 1987;147:251_3.18. Gordon SG, Cross BA. A factor X-activating cysteine protease from malignant tissue. J Clin Invest. 1981 Jun;67(6):1665-71.19. Schved JF, Dupuy-Fons C, Biron C, Quere I, Janbon C. A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) Study. Haemostasis. 1994 May-Jun;24(3):175-82.Tanne D, D'Olhaberriague L, Trivedi AM, Salowich-Palm L, Schultz LR, Levine SR. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology. 2002 Mar-Apr;21(2):93-9.1. Tanne D, D'Olhaberriague L, Trivedi AM, Salowich-Palm L, Schultz LR, Levine SR. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology. 2002 Mar-Apr;21(2):93-9.References1. Raschi E, Testoni C, Borghi MO, Fineschi S, Meroni PL. Endothelium activation in the anti-phospholipid syndrome. Biomed Pharmacother. 2003 Sep;57(7):282-6.2. Vermylen J, Van Geet C, Arnout J. Antibody-mediated thrombosis: relation to the antiphospholipid syndrome. Lupus. 1998;7 Suppl 2:S63-6.3. Roubey RA. Update on antiphospholipid antibodies. Curr Opin Rheumatol. 2000 Sep;12(5):374-8.4. Ishikura K, Wada H, Kamikura Y, Hattori K, Fukuzawa T, Yamada N, et al. High prevalence of anti-prothrombin antibody in patients with deep vein thrombosis. Am J Hematol. 2004 Aug;76(4):338-42.5. Pierangeli SS, Harris EN. Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. Lupus. 2003;12(7):539-45.6. Miesbach W. Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment. Semin Thromb Hemost. 2008 Apr;34(3):282-5.7. Timuragaoglu A, Duman A, Ongut G, Saka O, Karadogan I. The significance of autoantibodies in non-Hodgkin's lymphoma. Leuk Lymphoma. 2000 Dec;40(1-2):119-22.8. Stasi R, Stipa E, Masi M, Oliva F, Sciarra A, Perrotti A, et al. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma. Thromb Haemost. 1993 Oct 18;70(4):568-72.9. Lossos IS, Bogomolski-Yahalom V, Matzner Y. Anticardiolipin antibodies in acute myeloid leukemia: prevalence and clinical significance. Am J Hematol. 1998 Feb;57(2):139-43.10. Malnick SD, Geltner D, Sthoeger Z. Anticardiolipin antibody associated with renal carcinoma. J Rheumatol. 1995 Oct;22(10):2007-8.11. Yoon KH, Wong A, Shakespeare T, Sivalingam P. High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus. 2003;12(2):112-6.12. Ozguroglu M, Arun B, Erzin Y, Demir G, Demirelli F, Mandel NM, et al. Serum cardiolipin antibodies in cancer patients with thromboembolic events. Clin Appl Thromb Hemost. 1999 Jul;5(3):181-4.13. Sack GH, Jr., Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 1977 Jan;56(1):1-37.14. Aderka D, Brown A, Zelikovski A, Pinkhas J. Ideopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer. 1986;57:1846_9.15. Lieberman JS, Borrero J, Urdaneta E, Wright IS. Thrombophlebitis and cancer. JAMA. 1961 Aug 26;177:542-5.16. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998 Apr 23;338(17):1169-73.17. Goldberg R, Seneff M, Gore J, Anderson F, Greene H, Wheeler H, et al. Occult malignant neoplasm in patient with deep venous thrombosis. Arch Intern Med 1987;147:251_3.18. Gordon SG, Cross BA. A factor X-activating cysteine protease from malignant tissue. J Clin Invest. 1981 Jun;67(6):1665-71.19. Schved JF, Dupuy-Fons C, Biron C, Quere I, Janbon C. A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) Study. Haemostasis. 1994 May-Jun;24(3):175-82.20.Tanne D, D'Olhaberriague L, Trivedi AM, Salowich-Palm L, Schultz LR, Levine SR. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology. 2002 Mar-Apr;21(2):93-9. |
| Idioma: | Inglés |
1 Health and Education - 2 por Akbari, Mohammad Esmaeil | 6 Effectiveness of Mindfulness-Based Cognitive Therapy on Reduction of Depression and Anxiety Symptoms in Mothers of Children With Cancer por Mehranfar, Mojtaba; Dept. of Counselling, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran,Younesi, Jalal; Dept. of Counselling, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran,Banihashem, Abdollah; Dept. of Internal Medicine and Paediatrics, University of
Medical Sciences, Mashhad, Iran |
2 The Study of DNA Methylation of bax Gene Promoter in Breast and Colorectal Carcinoma Cell Lines por Alipour, Mohsen; Dept. of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran,Zargar, Seyed Jalal; Dept. of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran,Safarian, Shahrokh; Dept. of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran,Fouladdel, Shamile; Dept. of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran,Azizi, Ebrahim; Dept. of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran,Jafargholizadeh, Naser; Dept. of Cell & Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran | 7 Prevention and Management of Mucositis in Patients With Cancer: a Review Article por [wlia, ّatemeh; Dept. of Oral Medicine, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran,«azemeini, ُeidkazem; Burn hospital, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran,gholami, neda; Dept. of Oral Medicine, Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran |
3 Cancer Prevention; Cancer Risk Management por Akbari, Mohammad Esmaeil | 8 Psychosocial Care for Breast Cancer: Physicians' Perspective por Kaviani, Ahmad; Department of surgery, Tehran University of Medical Sciences, Tehran, Iran,Mehrdad, N; Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR), Tehran, Iran,Yunesian, M; school of Public Health , Environmental Research Center, Tehran University of Medical Sciences, Tehran, Iran,Shakiba, B; Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran,Ebrahimi, M; Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR), Tehran, Iran,Majidzadeh, K; Iranian Center for Breast Cancer (ICBC), Academic Center for Education, Culture and Research (ACECR), Tehran, Iran,Akbari, ME; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
4 Euthanasia in Cancer Patients, Islamic Point of View por Mousavi, SM; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Akbari, A; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Akbari, ME; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Najd Sepas, H; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran | 9 Cell Survival Entropy and Cellular Resistance Activation Dose: Effect of Calprotectin on Gastric Adenocarcinoma Cell Line por Rezaei-Tavirani, Mostafa,Rahmati-Roodsari, Mohammad,Mirzaie, Mehdi,Amini Geram, Pooneh,Sobhi, Sara |
5 Evaluation of Prognostic Factors In Patients with Metastatic Breast Cancer por Saeidi Saedi, H,Seilanian Toosi, M,Mirsadraei, M,Roodbari, S | 10 “Vitality” a Missing Link in Adjustment to Childhood Cancer por Firoozi, M; Department of Psychology, Tehran University, Tehran, Iran,Besharat, MA; Department of Psychology, Tehran University, Tehran, Iran,Farahani, H; Department of Psychology, Tehran University, Tehran, Iran,Ghaed Rahmat, A; Department of Psychology, Tabatabayi University, Tehran, Iran |